FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Zelig Eshhar

Research Profile

Living Beings

Chemicals & Drugs

Physiology

Disorders

Prostatic Neoplasms

Concepts & Ideas

Molecular Sequence Data

Co-author Network

Publications

TOP 3
Amit Maliar; Charlotte Servais; Tova Waks; Ron Lavy; Hinrich Abken; Peter Altevogt; Markus Chmielewski; Zelig Eshhar
Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice.
Rami Fishler; Elad Peer; Yoram Reiter; Arbel Artzy-Schnirman; Reuven Brener; Zelig Eshhar; Tova Waks; Ron Wolchinsky; Uri Sivan
Mixed alkanethiol monolayers on submicrometric gold patterns: a controlled platform for studying cell-ligand interactions.
Assaf Marcus; Zelig Eshhar
Tumor-specific allogeneic cells for cancer therapy.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Zelig Eshhar (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Amit Maliar; Charlotte Servais; Tova Waks; Ron Lavy; Hinrich Abken; Peter Altevogt; Markus Chmielewski; Zelig Eshhar
Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice.
Gastroenterology 2012;143(5):1375-84.e1-5.
2012: Rami Fishler; Elad Peer; Yoram Reiter; Arbel Artzy-Schnirman; Reuven Brener; Zelig Eshhar; Tova Waks; Ron Wolchinsky; Uri Sivan
Mixed alkanethiol monolayers on submicrometric gold patterns: a controlled platform for studying cell-ligand interactions.
Nano letters 2012;12(9):4992-6.
2011: Assaf Marcus; Zelig Eshhar
Tumor-specific allogeneic cells for cancer therapy.
Expert opinion on biological therapy 2011;11(12):1551-4.
2011: Arbel Artzy-Schnirman; Itai Benhar; Dan Blat; Zelig Eshhar; Rami Fishler; Dori Gertman; Ravit Oren; Uri Sivan; Yael Talmon; Tova Waks; Ron Wolchinsky; Yoram Reiter
Electrically controlled molecular recognition harnessed to activate a cellular response.
Nano letters 2011;11(11):4997-5001.
2011: Assaf Marcus; Tova Waks; Zelig Eshhar
Redirected tumor-specific allogeneic T cells for universal treatment of cancer.
Blood 2011;118(4):975-83.
2011: Assaf Marcus; Zelig Eshhar
Allogeneic adoptive cell transfer therapy as a potent universal treatment for cancer.
Oncotarget 2011;2(7):525-6.
2010: Robert E Hawkins; David Gilham; Reno Debets; Zelig Eshhar; Naomi Taylor; Hinrich Abken; Ton N Schumacher
Development of adoptive cell therapy for cancer: a clinical perspective.
Human gene therapy 2010;21(6):665-72.
2010: Zelig Eshhar
Adoptive cancer immunotherapy using genetically engineered designer T-cells: First steps into the clinic.
Current opinion in molecular therapeutics 2010;12(1):55-63.
2009: Yangbing Zhao; Qiong J Wang; Shicheng Yang; James N Kochenderfer; Zhili Zheng; Xiaosong Zhong; Michel Sadelain; Zelig Eshhar; STEVEN ROSENBERG; Richard A Morgan
A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity.
Journal of immunology (Baltimore, Md. : 1950) 2009;183(9):5563-74.
2009: Itai Kela; Alon Harmelin; Tova Waks; Avi Orr-Urtreger; Eytan Domany; Zelig Eshhar
Interspecies comparison of prostate cancer gene-expression profiles reveals genes associated with aggressive tumors.
The Prostate 2009;69(10):1034-44.
2009: Eran Elinav; Nitzan Adam; Tova Waks; Zelig Eshhar
Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor.
Gastroenterology 2009;136(5):1721-31.
2008: Eran Elinav; Tova Waks; Zelig Eshhar
Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice.
Gastroenterology 2008;134(7):2014-24.
2008: Lilach Agemy; Alon Harmelin; Tova Waks; Ilan Leibovitch; Tatyana Rabin; M Raphael Pfeffer; Zelig Eshhar
Irradiation enhances the metastatic potential of prostatic small cell carcinoma xenografts.
The Prostate 2008;68(5):530-9.
2008: Zelig Eshhar
The T-body approach: redirecting T cells with antibody specificity.
Handbook of experimental pharmacology 2008;(181):329-42.
2006: Michael H Kershaw; Jennifer A Westwood; Linda L Parker; Gang Wang; Zelig Eshhar; Sharon A Mavroukakis; Donald E White; John R Wunderlich; Silvana Canevari; Linda Rogers-Freezer; Clara C Chen; James C Yang; STEVEN ROSENBERG; Patrick Hwu
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(20 Pt 1):6106-15.
2006: niv papo; Dalia Seger; Arik Makovitzki; Vyacheslav Kalchenko; Zelig Eshhar; Hadassa Degani; Yechiel Shai
Inhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense-like lytic peptide.
Cancer research 2006;66(10):5371-8.
2005: Zelig Eshhar; Tova Waks; Jehonathan Pinthus
Redirecting immune cells against bone metastases: Immunotherapy of prostate cancer metastases using genetically programmed immune effector cells.
Discovery medicine 2005;5(27):259-64.
2005: Dinorah Friedmann-Morvinski; Alain Bendavid; Tova Waks; Daniel Schindler; Zelig Eshhar
Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation.
Blood 2005;105(8):3087-93.
2005: Bose S Kochupurakkal; Daniel Harari; Ayelet Di-Segni; Galia Maik-Rachline; Ljuba Lyass; Gal Gur; Gabriele Kerber; Ami Citri; Sara Lavi; Raya Eilam; Vered Chalifa-Caspi; Zelig Eshhar; Eli Pikarsky; Ronit Pinkas-Kramarski; Sarah S Bacus; Yosef Yarden
Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity.
The Journal of biological chemistry 2005;280(9):8503-12.
2004: Jehonathan H Pinthus; Tova Waks; Victoria Marcu (-Malina); Keren Kaufman-Francis; Alon Harmelin; Itzhak Aizenberg; Hannah Kanety; Jacob Ramon; Zelig Eshhar
Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes.
The Journal of clinical investigation 2004;114(12):1774-81.
2004: Jehonathan H Pinthus; Eduard Fridman; Benjamin Dekel; I Goldberg; Keren Kaufman-Francis; Zelig Eshhar; Alon Harmelin; Gideon Rechavi; Orna Mor; Jacob Ramon; Yoram Mor
ErbB2 is a tumor associated antigen and a suitable therapeutic target in Wilms tumor.
The Journal of urology 2004;172(4 Pt 2):1644-8.
2004: niv papo; Amir Braunstein; Zelig Eshhar; Yechiel Shai
Suppression of human prostate tumor growth in mice by a cytolytic D-, L-amino Acid Peptide: membrane lysis, increased necrosis, and inhibition of prostate-specific antigen secretion.
Cancer research 2004;64(16):5779-86.
2004: Vicki Plaks; Natalia V Koudinova; Uri Nevo; Jehonathan H Pinthus; Hannah Kanety; Zelig Eshhar; Jacob Ramon; Avigdor Scherz; Michal Neeman; Yoram Salomon
Photodynamic therapy of established prostatic adenocarcinoma with TOOKAD: a biphasic apparent diffusion coefficient change as potential early MRI response marker.
Neoplasia (New York, N.Y.) 2004;6(3):224-33.
2003: Jehonathan H Pinthus; Tova Waks; Keren Kaufman-Francis; Daniel G Schindler; Alon Harmelin; Hannah Kanety; Jacob Ramon; Zelig Eshhar
Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes.
Cancer research 2003;63(10):2470-6.
2003: Natalia V Koudinova; Jehonathan H Pinthus; Alexander Brandis; Ori Brenner; Peter Bendel; Jacob Ramon; Zelig Eshhar; Avigdor Scherz; Yoram Salomon
Photodynamic therapy with Pd-Bacteriopheophorbide (TOOKAD): successful in vivo treatment of human prostatic small cell carcinoma xenografts.
International journal of cancer. Journal international du cancer 2003;104(6):782-9.
2003: Nava Levit-Binnun; Ariel B Lindner; Ory Zik; Zelig Eshhar; Elisha Moses
Quantitative detection of protein arrays.
Analytical chemistry 2003;75(6):1436-41.
2002: Anat Bar-Shira; Jehonathan H Pinthus; Uri Rozovsky; Myriam Goldstein; William R Sellers; Yuval Yaron; Zelig Eshhar; Avi Orr-Urtreger
Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft.
Cancer research 2002;62(23):6803-7.
2002: Odile Cohen-Haguenauer; Felicia Rosenthal; Bernd Gänsbacher; Reinder L H Bolhuis; Karoline Dorsch-Häsler; Zelig Eshhar; Gösta Gahrton; Peter Hokland; Cecilia Melani; Elaine Rankin; Kris Thielemans; Richard Vile; Heinz Zwierzina; Klaus Cichutek
Opinion paper on the current status of the regulation of gene therapy in Europe.
Human gene therapy 2002;13(17):2085-110.
2002: Ariel B Lindner; Se Ho Kim; Daniel G Schindler; Zelig Eshhar; Dan S Tawfik
Esterolytic antibodies as mechanistic and structural models of hydrolases-a quantitative analysis.
Journal of molecular biology 2002;320(3):559-72.
2002: Anat David; Nicola J Mabjeesh; Idit Azar; Sharon Biton; Sharon Engel; Jeanne Bernstein; Jacob Romano; Yoav Avidor; Tova Waks; Zelig Eshhar; Salomon Z Langer; Beatriz Lifschitz-Mercer; Haim Matzkin; Galit Rotman; Amir Toporik; Kinneret Savitsky; Liat Mintz
Unusual alternative splicing within the human kallikrein genes KLK2 and KLK3 gives rise to novel prostate-specific proteins.
The Journal of biological chemistry 2002;277(20):18084-90.
2002: zohar gavish; Jehonathan H Pinthus; Vivian Barak; Jacob Ramon; Arnon Nagler; Zelig Eshhar; Mark Pines
Growth inhibition of prostate cancer xenografts by halofuginone.
The Prostate 2002;51(2):73-83.
2001: Zelig Eshhar; Tova Waks; A Bendavid; Daniel G Schindler
Functional expression of chimeric receptor genes in human T cells.
Journal of immunological methods 2001;248(1-2):67-76.
2000: Jehonathan H Pinthus; Tova Waks; Daniel G Schindler; Alon Harmelin; J W Said; A Belldegrun; Jacob Ramon; Zelig Eshhar
WISH-PC2: a unique xenograft model of human prostatic small cell carcinoma.
Cancer research 2000;60(23):6563-7.
2000: T Daly; Richard E Royal; Michael H Kershaw; J Treisman; G Wang; W Li; D Herlyn; Zelig Eshhar; Patrick Hwu
Recognition of human colon cancer by T cells transduced with a chimeric receptor gene.
Cancer gene therapy 2000;7(2):284-91.
1999: Ariel B Lindner; Zelig Eshhar; Dan S Tawfik
Conformational changes affect binding and catalysis by ester-hydrolysing antibodies.
Journal of molecular biology 1999;285(1):421-30.
1998: Benoît Gigant; Jean-Baptiste Charbonnier; Zelig Eshhar; Bernard S Green; Marcel Knossow
Crossreactivity, efficiency and catalytic specificity of an esterase-like antibody.
Journal of molecular biology 1998;284(3):741-50.
1998: Delia Mezzanzanica; Silvana Canevari; Alessandra Mazzoni; Mariangela Figini; MI Colnaghi; Tova Waks; Daniel G Schindler; Zelig Eshhar
Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells.
Cancer gene therapy 1998;5(6):401-7.
1998: Cecilia Melani; Mariangela Figini; D Nicosia; Elena Luison; V Ramakrishna; G Casorati; Giorgio Parmiani; Zelig Eshhar; Silvana Canevari; Mario P Colombo
Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody.
Cancer research 1998;58(18):4146-54.
1998: Cheryl Fitzer-Attas; Daniel G Schindler; Tova Waks; Zelig Eshhar
Harnessing Syk family tyrosine kinases as signaling domains for chimeric single chain of the variable domain receptors: optimal design for T cell activation.
Journal of immunology (Baltimore, Md. : 1950) 1998;160(1):145-54.
1997: Zelig Eshhar
Tumor-specific T-bodies: towards clinical application.
Cancer immunology, immunotherapy : CII 1997;45(3-4):131-6.
1997: Se Ho Kim; Daniel G Schindler; Ariel B Lindner; Dan S Tawfik; Zelig Eshhar
Expression and characterization of recombinant single-chain Fv and Fv fragments derived from a set of catalytic antibodies.
Molecular immunology 1997;34(12-13):891-906.
1997: Benoît Gigant; Jean-Baptiste Charbonnier; Zelig Eshhar; Bernard S Green; Marcel Knossow
X-ray structures of a hydrolytic antibody and of complexes elucidate catalytic pathway from substrate binding and transition state stabilization through water attack and product release.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(15):7857-61.
1997: Benoît Gigant; Jean-Baptiste Charbonnier; Béatrice Golinelli-Pimpaneau; R R Zemel; Zelig Eshhar; Bernard S Green; Marcel Knossow
Mechanism of inactivation of a catalytic antibody by p-nitrophenyl esters.
European journal of biochemistry / FEBS 1997;246(2):471-6.
1997: Cheryl Fitzer-Attas; Daniel G Schindler; Tova Waks; Zelig Eshhar
Direct T cell activation by chimeric single chain Fv-Syk promotes Syk-Cbl association and Cbl phosphorylation.
The Journal of biological chemistry 1997;272(13):8551-7.
1997: Dan S Tawfik; Ariel B Lindner; R Chap; Zelig Eshhar; Bernard S Green
Efficient and selective p-nitrophenyl-ester-hydrolyzing antibodies elicited by a p-nitrobenzyl phosphonate hapten.
European journal of biochemistry / FEBS 1997;244(2):619-26.
1997: Jean-Baptiste Charbonnier; Béatrice Golinelli-Pimpaneau; Benoît Gigant; Dan S Tawfik; R Chap; Daniel G Schindler; Se Ho Kim; Bernard S Green; Zelig Eshhar; Marcel Knossow
Structural convergence in the active sites of a family of catalytic antibodies.
Science (New York, N.Y.) 1997;275(5303):1140-2.
1996: J Lustgarten; Tova Waks; Zelig Eshhar
Prolonged inhibition of IgE production in mice following treatment with an IgE-specific immunotoxin.
Molecular immunology 1996;33(3):245-51.
1996: Zelig Eshhar; N Bach; Cheryl Fitzer-Attas; G Gross; J Lustgarten; Tova Waks; Daniel G Schindler
The T-body approach: potential for cancer immunotherapy.
Springer seminars in immunopathology 1996;18(2):199-209.
1995: Jean-Baptiste Charbonnier; E Carpenter; Benoît Gigant; Béatrice Golinelli-Pimpaneau; Zelig Eshhar; Bernard S Green; Marcel Knossow
Crystal structure of the complex of a catalytic antibody Fab fragment with a transition state analog: structural similarities in esterase-like catalytic antibodies.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(25):11721-5.
1995: G Gross; S Levy; Ronald Levy; Tova Waks; Zelig Eshhar
Chimaeric T-cell receptors specific to a B-lymphoma idiotype: a model for tumour immunotherapy.
Biochemical Society transactions 1995;23(4):1079-82.
1995: J Lustgarten; Zelig Eshhar
Specific elimination of IgE production using T cell lines expressing chimeric T cell receptor genes.
European journal of immunology 1995;25(10):2985-91.
1995: Dan S Tawfik; R Chap; Bernard S Green; Michael Sela; Zelig Eshhar
Unexpectedly high occurrence of catalytic antibodies in MRL/lpr and SJL mice immunized with a transition-state analog: is there a linkage to autoimmunity?
Proceedings of the National Academy of Sciences of the United States of America 1995;92(6):2145-9.
1994: Béatrice Golinelli-Pimpaneau; Benoît Gigant; T Bizebard; Jorge Navaza; P Saludjian; R Zemel; Dan S Tawfik; Zelig Eshhar; Bernard S Green; Marcel Knossow
Crystal structure of a catalytic antibody Fab with esterase-like activity.
Structure (London, England : 1993) 1994;2(3):175-83.
1994: Dan S Tawfik; R Chap; Zelig Eshhar; Bernard S Green
pH on-off switching of antibody-hapten binding by site-specific chemical modification of tyrosine.
Protein engineering 1994;7(3):431-4.
1994: R Zemel; Daniel G Schindler; Dan S Tawfik; Zelig Eshhar; Bernard S Green
Differences in the biochemical properties of esterolytic antibodies correlate with structural diversity.
Molecular immunology 1994;31(2):127-37.
1994: Dan S Tawfik; Zelig Eshhar; Bernard S Green
Catalytic antibodies: a critical assessment.
Molecular biotechnology 1994;1(1):87-103.
1994: N L Bach; Tova Waks; Daniel G Schindler; Zelig Eshhar
Functional expression in mast cells of chimeric receptors with antibody specificity.
Cell biophysics 1994;24-25():229-36.
1993: I Stancovski; Daniel G Schindler; Tova Waks; Yosef Yarden; Michael Sela; Zelig Eshhar
Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors.
Journal of immunology (Baltimore, Md. : 1950) 1993;151(11):6577-82.
1993: G Gorochov; G Gross; Tova Waks; Zelig Eshhar
Anti-leucocyte function-associated antigen-1 antibodies inhibit T-cell activation following low-avidity and adhesion-independent interactions.
Immunology 1993;79(4):548-55.
1993: A Nissim; S Schwarzbaum; R Siraganian; Zelig Eshhar
Fine specificity of the IgE interaction with the low and high affinity Fc receptor.
Journal of immunology (Baltimore, Md. : 1950) 1993;150(4):1365-74.
1993: Zelig Eshhar; Tova Waks; G Gross; Daniel G Schindler
Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(2):720-4.
1993: Dan S Tawfik; Bernard S Green; R Chap; Michael Sela; Zelig Eshhar
catELISA: a facile general route to catalytic antibodies.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(2):373-7.
1992: A Nissim; Zelig Eshhar
The human mast cell receptor binding site maps to the third constant domain of immunoglobulin E.
Molecular immunology 1992;29(9):1065-72.
1992: M Glikson; R Arad-Yellin; M Ghozi; L Raveh; Bernard S Green; Zelig Eshhar
Characterization of soman-binding antibodies raised against soman analogs.
Molecular immunology 1992;29(7-8):903-10.
1992: Dan S Tawfik; Bernard S Green; Zelig Eshhar
Detection of catalytic monoclonal antibodies.
Analytical biochemistry 1992;202(1):35-9.
1992: G Gorochov; J Lustgarten; Tova Waks; G Gross; Zelig Eshhar
Functional assembly of chimeric T-cell receptor chains.
International journal of cancer. Supplement = Journal international du cancer. Supplement 1992;7():53-7.
1991: J Lustgarten; Tova Waks; Zelig Eshhar
CD4 and CD8 accessory molecules function through interactions with major histocompatibility complex molecules which are not directly associated with the T cell receptor-antigen complex.
European journal of immunology 1991;21(10):2507-15.
1991: Ido Lubin; Y Faktorowich; Tsvee Lapidot; Y Gan; Zelig Eshhar; E Gazit; Mia Levite; Yair Reisner
Engraftment and development of human T and B cells in mice after bone marrow transplantation.
Science (New York, N.Y.) 1991;252(5004):427-31.
1991: A Nissim; Zelig Eshhar
Localization of the Fc epsilon RI binding site to the third constant domain of IgE.
International archives of allergy and applied immunology 1991;94(1-4):93-5.
1991: A Nissim; M H Jouvin; Zelig Eshhar
Mapping of the high affinity Fc epsilon receptor binding site to the third constant region domain of IgE.
The EMBO journal 1991;10(1):101-7.
1990: Dan S Tawfik; R R Zemel; R Arad-Yellin; Bernard S Green; Zelig Eshhar
Simple method for selecting catalytic monoclonal antibodies that exhibit turnover and specificity.
Biochemistry 1990;29(42):9916-21.
1989: G Gross; Tova Waks; Zelig Eshhar
Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(24):10024-8.
1989: Daniela Novick; D G Fischer; Z Reiter; Zelig Eshhar; Menachem Rubinstein
Monoclonal antibodies to the human interferon-gamma receptor: blocking of the biological activities of interferon-gamma and purification of the receptor.
Journal of interferon research 1989;9(3):315-28.
1989: S Schwarzbaum; A Nissim; I Alkalay; M C Ghozi; Daniel G Schindler; Yehudit Bergman; Zelig Eshhar
Mapping of murine IgE epitopes involved in IgE-Fc epsilon receptor interactions.
European journal of immunology 1989;19(6):1015-23.
1989: G Gross; G Gorochov; Tova Waks; Zelig Eshhar
Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity.
Transplantation proceedings 1989;21(1 Pt 1):127-30.
1988: M Baniyash; M Kehry; Zelig Eshhar
Anti-IgE monoclonal antibodies directed at the Fc epsilon receptor binding site.
Molecular immunology 1988;25(8):705-11.
1987: M Baniyash; Zelig Eshhar
Anti-anti-IgE idiotypic antibodies mimic IgE in their binding to the Fc epsilon receptor.
European journal of immunology 1987;17(9):1337-42.
1983: S Horowitz; Rebeca Tarrab-Hazdai; Zelig Eshhar; Ruth Arnon
Anti-schistosome monoclonal antibodies of different isotypes--correlation with cytotoxicity.
The EMBO journal 1983;2(2):193-8.
1983: Daniela Novick; Zelig Eshhar; D G Fischer; J Friedlander; Menachem Rubinstein
Monoclonal antibodies to human interferon-gamma: production, affinity purification and radioimmunoassay.
The EMBO journal 1983;2(9):1527-30.
1968: Leonora Reinhold; Zelig Eshhar
Transport of 3-o-Methylglucose Into and Out of Storage Cells of Daucus carota.
Plant physiology 1968;43(7):1023-30.